Your browser is no longer supported. Please, upgrade your browser.
Settings
TROV TrovaGene, Inc. daily Stock Chart
TROV [NASD]
TrovaGene, Inc.
Index- P/E- EPS (ttm)-2.87 Insider Own0.40% Shs Outstand22.86M Perf Week-11.40%
Market Cap14.18M Forward P/E- EPS next Y-0.55 Insider Trans82.01% Shs Float21.66M Perf Month-20.49%
Income-17.70M PEG- EPS next Q-0.16 Inst Own10.40% Short Float10.72% Perf Quarter-22.48%
Sales0.50M P/S28.36 EPS this Y44.70% Inst Trans2.50% Short Ratio1.75 Perf Half Y-23.43%
Book/sh0.68 P/B0.91 EPS next Y- ROA-113.30% Target Price3.00 Perf Year-88.77%
Cash/sh- P/C- EPS next 5Y- ROE-165.70% 52W Range0.62 - 5.82 Perf YTD-83.19%
Dividend- P/FCF- EPS past 5Y4.10% ROI-349.40% 52W High-89.34% Beta0.12
Dividend %- Quick Ratio6.00 Sales past 5Y2.30% Gross Margin- 52W Low0.68% ATR0.05
Employees17 Current Ratio6.00 Sales Q/Q0.00% Oper. Margin- RSI (14)27.61 Volatility7.50% 6.75%
OptionableYes Debt/Eq0.00 EPS Q/Q87.10% Profit Margin- Rel Volume0.21 Prev Close0.64
ShortableYes LT Debt/Eq0.00 EarningsNov 15 AMC Payout- Avg Volume1.32M Price0.62
Recom2.00 SMA20-12.96% SMA50-22.81% SMA200-66.10% Volume282,265 Change-3.84%
Dec-21-17Initiated H.C. Wainwright Buy $1
Nov-10-17Downgrade Maxim Group Buy → Hold
Apr-12-17Upgrade Maxim Group Hold → Buy $4
Mar-16-17Downgrade Piper Jaffray Neutral → Underweight
Mar-16-17Downgrade Maxim Group Buy → Hold
Aug-08-16Upgrade Cantor Fitzgerald Hold → Buy
Aug-05-16Reiterated Maxim Group Buy $12 → $9
Jul-07-16Initiated Maxim Group Buy $12
Apr-26-16Downgrade Leerink Partners Outperform → Mkt Perform
Apr-25-16Downgrade Piper Jaffray Overweight → Neutral
Apr-25-16Downgrade Cantor Fitzgerald Buy → Hold $9 → $5
Feb-03-16Reiterated Maxim Group Buy $13 → $12
Sep-16-15Initiated Cantor Fitzgerald Buy
Aug-14-15Initiated Leerink Partners Outperform
Apr-20-15Reiterated Maxim Group Buy $10 → $13
Jul-10-14Initiated Maxim Group Buy $10
Nov-13-13Reiterated Aegis Capital Buy $14 → $10
Oct-01-13Reiterated Aegis Capital Buy $14
Jul-16-13Initiated Cantor Fitzgerald Buy $10
Apr-01-13Reiterated Aegis Capital Buy $12 → $14
Dec-11-18 08:15AM  Trovagene (TROV) Stock: Providing New Cancer Treatment Options With Onvansertib ACCESSWIRE
Dec-03-18 11:00AM  New Data from Phase 1b/2 Study of Onvansertib in Combination with LDAC or Decitabine Demonstrates Response to Treatment in Relapsed/Refractory AML PR Newswire
Nov-21-18 02:14PM  What does TrovaGene Incs (NASDAQ:TROV) Balance Sheet Tell Us About Its Future? Simply Wall St.
Nov-19-18 08:50AM  Detailed Research: Economic Perspectives on Miller Industries, P & F Industries, Schmitt Industries, Orgenesis, AMERI, and TrovaGene What Drives Growth in Today's Competitive Landscape GlobeNewswire
Nov-15-18 08:30AM  Trovagene, Inc. Receives Positive Nasdaq Listing Decision PR Newswire
Nov-13-18 08:30AM  Trovagene Announces Launch of New Company Website PR Newswire
Nov-07-18 04:20PM  Trovagene Announces Third Quarter 2018 Highlights and Financial Results PR Newswire
Nov-01-18 10:36AM  Trovagene to Present Data from Lead Clinical Program of Onvansertib in Acute Myeloid Leukemia at the 60th American Society of Hematology Annual Meeting PR Newswire +14.63%
Oct-24-18 08:30AM  Trovagene Announces New Patent Claim Allowances Affirming Broad Patent Portfolio Coverage of NPM1 Mutations by U.S. Patent and Trademark Office PR Newswire -6.85%
Oct-18-18 08:30AM  Trovagene to Provide Update on Onvansertib Clinical Development Program on Wednesday, October 24, 2018 PR Newswire +10.48%
Oct-15-18 08:05AM  Trovagene Advances its Clinical Development of PCM-075, Analysts review and Target ACCESSWIRE +9.75%
Oct-08-18 08:00AM  Todays Research Reports on Stocks to Watch: GTx and TrovaGene ACCESSWIRE -11.05%
Oct-03-18 08:30AM  Trovagene Announces Exclusive License Agreement with MIT for Combination Therapy of Anti-Androgens and Polo-like Kinase Inhibitors in Prostate Cancer PR Newswire
Sep-27-18 08:30AM  Trovagene Announces Completion of Dosing Cohort of Patients Treated with Onvansertib in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial PR Newswire
Sep-18-18 02:47PM  Is TrovaGene Inc (NASDAQ:TROV) A Healthcare Industry Laggard Or Leader? Simply Wall St.
08:30AM  Trovagene Announces Participation at The MicroCap Conference on October 1st and 2nd at the Essex House in New York City PR Newswire
Aug-29-18 08:30AM  Trovagene Announces European Commission Grants Orphan Drug Designation to Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe PR Newswire
Aug-23-18 08:30AM  Trovagene Announces Participation at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City September 4-6, 2018 PR Newswire
Aug-16-18 08:00AM  Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial PR Newswire
Aug-15-18 08:00AM  Trovagene Receives USAN Approval for "Onvansertib" as Nonproprietary Name for First-in-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075 PR Newswire
Aug-03-18 06:30PM  Trovagene (TROV) Reports Q2 Loss, Tops Revenue Estimates Zacks
05:27PM  Trovagene: 2Q Earnings Snapshot Associated Press
05:15PM  Trovagene Announces Second Quarter 2018 Highlights and Financial Results PR Newswire
Aug-01-18 08:00AM  Trovagene Receives Positive Opinion for Orphan Drug Designation in the European Union for PCM-075, Trovagene's Investigational Cancer Drug PR Newswire -6.89%
Jul-27-18 07:45AM  Breakfast Technical Briefing on TrovaGene and Three Other Additional Medical Research Stocks ACCESSWIRE
Jul-09-18 08:00AM  Trovagene Presents Outlook for Second Half of 2018 PR Newswire
Jun-27-18 08:00AM  Trovagene Announces Preliminary Clinical Data from First Dosing Cohort Demonstrating Durable Treatment Effect of PCM-075 in Combination with Cytarabine or Decitabine in Patients with Relapsed or Refractory AML PR Newswire
Jun-25-18 06:00AM  TrovaGene Enters Oversold Territor Zacks
Jun-22-18 05:19PM  Trovagene Announces Leadership Change PR Newswire
Jun-21-18 08:00AM  Trovagene Announces the Start of Recruitment and Enrollment for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® in Patients with mCRPC PR Newswire
Jun-15-18 08:00AM  Trovagene Announces Completion of First Dosing Cohort of Patients Treated with PCM-075 in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial PR Newswire
Jun-12-18 01:05PM  Trovagene, Inc. Announces Closing of $18 Million Public Offering PR Newswire
Jun-11-18 08:10AM  Todays Research Reports on Stocks to Watch: Acorda Therapeutics and TrovaGene ACCESSWIRE -5.43%
Jun-08-18 07:49AM  TrovaGene (TROV) Enters Oversold Territory Zacks -48.02%
Jun-07-18 11:21PM  Trovagene, Inc. Announces Pricing of $18 Million Public Offering PR Newswire
May-31-18 05:00PM  Trovagene, Inc. Announces Reverse Stock Split PR Newswire
May-17-18 08:00AM  Trovagene Announces Completion of First Dosing Cohort of Patients in Ongoing Phase 1b/2 Trial of PCM-075 in Acute Myeloid Leukemia PR Newswire
May-16-18 11:55AM  Does TrovaGene Incs (NASDAQ:TROV) Past Performance Indicate A Stronger Future? Simply Wall St.
May-08-18 06:38PM  Trovagene: 1Q Earnings Snapshot Associated Press
04:15PM  Trovagene Announces First Quarter 2018 Highlights and Financial Results PR Newswire
Apr-17-18 02:00PM  Trovagene Presents Data at AACR Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with PCM-075 and Low-Dose Cytarabine PR Newswire -5.97%
Apr-16-18 09:00AM  Trovagene Presents Data at AACR Meeting 2018 Showing Synergy of PCM-075 in Combination with FLT3 Inhibitors in Acute Myeloid Leukemia (AML) PR Newswire
Apr-12-18 04:11PM  Trovagene Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2018 PR Newswire
Mar-20-18 08:00AM  Trovagene to Present at the 26th Annual Wall Street Investor Conference PR Newswire
Mar-05-18 08:00AM  Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial PR Newswire +33.87%
Feb-26-18 05:47PM  Trovagene reports 4Q loss Associated Press
04:42PM  Trovagene Announces Fourth Quarter and Full-Year 2017 Results PR Newswire
Feb-13-18 08:00AM  Trovagene Announces Activation of Two Additional Clinical Trial Sites to Conduct its Phase 1b/2 Study of PCM-075 in Patients with AML PR Newswire
Feb-09-18 03:15PM  Trovagene Presents Data Showing Synergy of PCM-075 in Combination with Zytiga® in Castration-Resistant Prostate Cancer Model at 2018 Genitourinary Cancers Symposium PR Newswire +24.43%
Feb-06-18 08:00AM  Trovagene Announces Completion of Cycle-One Dosing in First Patient Enrolled in its Phase 1b/2 Clinical Trial of PCM-075 in Acute Myeloid Leukemia (AML) PR Newswire +9.47%
Jan-24-18 07:43PM  Who Owns Most Of TrovaGene Inc (NASDAQ:TROV)? Simply Wall St.
08:00AM  Trovagene Announces Initiation of UNITE Phase 2 Clinical Trial of PCM-075 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) PR Newswire
Jan-08-18 01:02PM  Should You Be Concerned About TrovaGene Incs (NASDAQ:TROV) Risks? Simply Wall St. -6.83%
Jan-03-18 08:00AM  Trovagene to Present at the Biotech Showcase Annual Conference PR Newswire +11.08%
Jan-01-18 10:45AM  Is Now The Time To Bet On The Healthcare Sector And TrovaGene Inc (NASDAQ:TROV)? Simply Wall St.
Dec-22-17 01:25PM  Will TrovaGene Incs (NASDAQ:TROV) Earnings Grow In The Years Ahead? Simply Wall St.
Dec-21-17 08:00AM  Trovagene Announces Activation of Second Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075 PR Newswire +5.64%
Dec-15-17 11:40AM  Why TrovaGene Inc (TROV) Stock Tanked 40% Today SmarterAnalyst -41.31%
06:00AM  Trovagene Prices $4.5 Million Public Offering PR Newswire
Dec-14-17 08:00AM  Trovagene Submits Protocol to FDA for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® for Metastatic Castration-Resistant Prostate Cancer PR Newswire -6.50%
Dec-12-17 08:00AM  Trovagene Announces the Launch of NextCollect Urine Collection and DNA Preservation Kit to Research Laboratories and Pharmaceutical Customers PR Newswire
Dec-11-17 02:12PM  ETFs with exposure to TrovaGene, Inc. : December 11, 2017 Capital Cube
Dec-07-17 05:00PM  Trovagene Presents Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines to PCM-075 and Synergy with Zytiga® at San Antonio Breast Cancer Symposium (SABCS) PR Newswire
10:53AM  Interested In TrovaGene Inc (TROV)? Heres What Its Recent Track-Record Looks Like Simply Wall St.
Nov-30-17 02:30PM  ETFs with exposure to TrovaGene, Inc. : November 30, 2017 Capital Cube
Nov-29-17 07:53AM  TrovaGene, Inc. :TROV-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 Capital Cube
Nov-20-17 09:45AM  What does TrovaGene Incs (TROV) Balance Sheet Tell Us Abouts Its Future? Simply Wall St.
Nov-13-17 08:00AM  Trovagene Announces Activation of First Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075 PR Newswire
Nov-09-17 10:41AM  Trovagene reports 3Q loss Associated Press
10:32AM  Trovagene Announces Third Quarter 2017 Company Highlights and Financial Results PR Newswire
Nov-01-17 12:49PM  ETFs with exposure to TrovaGene, Inc. : November 1, 2017 Capital Cube +9.81%
Oct-18-17 08:00AM  Trovagene's PLK1 Inhibitor (PCM-075) Demonstrates Synergy with Zytiga® (abiraterone acetate) in Castration Resistant Prostate Cancer Tumor Cells PR Newswire +9.87%
Oct-10-17 11:52AM  ETFs with exposure to TrovaGene, Inc. : October 10, 2017 Capital Cube -6.99%
Oct-09-17 08:00AM  FDA Grants Orphan Drug Designation to Trovagene's PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia (AML) PR Newswire
Oct-04-17 10:26AM  When Will TrovaGene Inc (TROV) Run Out Of Cash? Simply Wall St.
Sep-20-17 08:00AM  Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis PR Newswire
Sep-19-17 08:09PM  What Does TrovaGene Incs (TROV) Share Price Indicate? Simply Wall St.
Aug-31-17 09:42PM  ETFs with exposure to TrovaGene, Inc. : September 1, 2017 Capital Cube -9.59%
08:00AM  Trovagene Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017 PR Newswire
Aug-30-17 07:02AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Trovagene, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire -5.19%
Aug-24-17 10:35AM  TrovaGene, Inc. :TROV-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-21-17 08:00AM  Trovagene's PLK1 Inhibitor PCM-075 Demonstrates Synergy with a HDAC Inhibitor in Non-Hodgkin Lymphoma Cell Lines PR Newswire
Aug-16-17 08:00AM  Trovagene's PLK1 Inhibitor PCM-075, in Preclinical AML Data, Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy PR Newswire
Aug-09-17 04:26PM  Trovagene Announces Second Quarter 2017 Company Highlights and Financial Results PR Newswire
Jul-28-17 05:35PM  Trovagene, Antonius Schuh and Stephen Zaniboni Resolve Employment Dispute PR Newswire -6.75%
Jul-27-17 08:00AM  Trovagene Announces FDA Approval of IND for Phase 1b/2 Trial of PCM-075 in Patients with Acute Myeloid Leukemia PR Newswire
Jul-26-17 08:30AM  Trovagene, Inc. Provides Company Overview and Discusses Clinical Development Plans for PCM-075 in New SNNLive Video Interview with StockNewsNow.com Accesswire -5.81%
Jul-25-17 08:00AM  Trovagene Announces Peer-Reviewed Publication of First-in-Human Phase 1 Trial Results with PCM-075, its Polo-like Kinase 1 (PLK1) Inhibitor PR Newswire
Jul-14-17 09:00AM  Trovagene Announces $7.1 Million Registered Direct Offering PR Newswire -20.57%
07:20AM  Featured Company News Trovagene Sells Its Proprietary Urine Collection And Nucleic Acid Preservation Device Nextcollect(TM) To Novogene Accesswire
Jul-12-17 08:00AM  Trovagene Announces Agreement with Novogene for NextCollect in China PR Newswire +10.69%
Jul-10-17 08:00AM  Trovagene, Inc. Regains Compliance with NASDAQ Listing Requirements PR Newswire
Jul-06-17 08:00AM  Trovagene Engages Leading CRO in AML to Conduct Phase 1b/2 Trial of PCM-075 PR Newswire -7.09%
Jun-29-17 08:00AM  Trovagene Announces Manufacturing Agreement with NerPharMa for Supply of PCM-075 for AML Trial PR Newswire +9.17%
Jun-27-17 08:00AM  Trovagene Announces Submission of Investigational New Drug Application to Initiate Phase 1b/2 Clinical Trial of PCM-075 for Acute Myeloid Leukemia PR Newswire
Jun-26-17 08:00AM  Trovagene Announces Expansion of Key Claims for its NPM1 Patent Portfolio for Acute Myeloid Leukemia PR Newswire
Jun-22-17 08:00AM  Trovagene Announces Agreement with Global Biopharmaceutical Company to Utilize Trovera® ctDNA Tests and Services in Cancer Clinical Trials PR Newswire +37.36%
Jun-12-17 08:00AM  Trovagene Enters Into Agreement with AstraZeneca to Utilize Trovera® ctDNA Test and Services in Prospective Biomarker Study PR Newswire +19.93%
Jun-05-17 02:51PM  ETFs with exposure to TrovaGene, Inc. : June 5, 2017 Capital Cube -7.62%
Jun-01-17 08:00AM  Trovagene to Present at the Marcum 2017 MicroCap Conference on June 15 in New York City PR Newswire +21.31%
Trovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) and has completed a Phase I clinical trial in advanced solid tumors. The PCM-075 is also in preclinical studies with approximately 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including Zytiga (abiraterone acetate); Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) in AML, metastatic castration-resistant prostate cancer and other hematologic and solid tumor cancers. Trovagene, Inc. primarily serves pharmaceutical companies and third party laboratories. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Erlander MarkChief Scientific OfficerOct 01Option Exercise0.007,500016,411Oct 03 05:09 PM
Markin Rodney SDirectorJun 20Buy0.8541,20035,02063,810Jun 21 04:30 PM
Tennant StanleyDirectorJun 08Buy0.8010,0008,000236,061Jun 11 06:03 AM
BRANCACCIO JOHN PDirectorJun 08Buy0.8010,0008,00053,167Jun 11 06:03 AM
WELCH WILLIAM JChief Executive OfficerJan 30Option Exercise0.00130,0000904,655Feb 01 04:30 PM
Erlander MarkChief Scientific OfficerJan 30Option Exercise0.0090,0000147,297Feb 01 04:30 PM
BRANCACCIO JOHN PDirectorJan 02Option Exercise0.0016,667043,167Jan 04 05:18 PM
WELCH WILLIAM JChief Executive OfficerJan 02Option Exercise0.0050,0000795,392Jan 04 05:16 PM
Tennant StanleyDirectorJan 02Option Exercise0.0016,6670234,545Jan 04 05:16 PM
JACOB GARY SDirectorJan 02Option Exercise0.0016,6670148,954Jan 04 05:15 PM
ADAMS THOMAS PHDDirectorJan 02Option Exercise0.0016,6670351,959Jan 04 05:15 PM
Billings PaulDirectorJan 02Option Exercise0.0016,667016,667Jan 04 05:16 PM
Markin Rodney SDirectorJan 02Option Exercise0.0016,667022,610Jan 04 05:15 PM
Erlander MarkChief Scientific OfficerJan 02Option Exercise0.0018,750066,801Jan 04 05:15 PM